Abstract
BackgroundBone marrow mesenchymal stem cells (BMMSCs) and bone marrow mononuclear cells (BMMNCs) are both used to treat spastic cerebral palsy. However, the differences in therapeutic effect remain unknown.MethodsA total of 105 patients with spastic cerebral palsy were enrolled and randomly assigned to three groups: the BMMSC group, the BMMNC group and the control group. Patients in both transplantation groups received four intrathecal cell injections. Patients in the control group received Bobath therapy. The gross motor function measure (GMFM) and the fine motor function measure (FMFM) were used to evaluate the therapeutic efficacy before transplantation and 3, 6, and 12 months after transplantation.ResultsThree months after cell transplantation, scores in the A dimension of GMFM and the A and C dimensions of FMFM scores in the BMMSC group are all higher than those of the BMMNC and the control groups (P < 0.05). Six months after cell transplantation, scores in the A, B dimensions of GMFM and the A, B, C, D, and E dimensions of FMFM scores in the BMMSC group are higher than those of the BMMNC and the control groups (P < 0.05). Twelve months after cell transplantation, scores in the A, B, and C dimensions of GMFM and the A, B, C, D, and E dimensions of FMFM scores in the BMMSC group are all higher than those of the BMMNC and the control groups (P < 0.05). No obvious adverse effects were investigated during follow-up.ConclusionsBMMSC transplantation for the treatment of cerebral palsy is safe and feasible, and can improve gross motor and fine motor function significantly. In addition, compared with BMMNC, the motor function of children improved significantly in terms of gross motor and fine motor functions.
Highlights
Bone marrow mesenchymal stem cells (BMMSCs) and bone marrow mononuclear cells (BMMNCs) are both used to treat spastic cerebral palsy
The study processes were blinded to the patients in the BMMSC and BMMNC groups, participant surgeons, coordinators, and the investigators who were responsible for patient assessment
The general details, as well as gross motor function measure (GMFM) and fine motor function measure (FMFM) scores are provided in Additional file 1, Tables 1 and 2
Summary
Bone marrow mesenchymal stem cells (BMMSCs) and bone marrow mononuclear cells (BMMNCs) are both used to treat spastic cerebral palsy. Cell transplantation in the treatment of spastic CP has resulted in positive effects in both animal experiments and clinical studies [4,5,6,7]. Research has confirmed that treatment with bone marrow mononuclear cell (BMMNC) transplantation has had positive and significant effects for spastic CP [4]. These encouraging results indicate that cell transplantation for the treatment of spastic CP has broad prospects in the field. Whether BMMSC and BMMNC from bone marrow have any difference of curative effect for the treatment of spastic CP remains unreported. To understand whether there are any significant differences between BMMSC and BMMNC transplantation, and between BMMSC and BMMNC and traditional rehabilitation treatment for children with spastic CP, we designed this experiment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
